2022 Pivotal Points, Currents and Controversies in nr-axSpA: What You May Have Missed

Target Audience
This educational activity has been designed to meet the needs of rheumatologists, internal medicine physicians, and other clinicians who manage patients with nonradiographic axial spondyloarthritis (nr-axSpA), including rheumatology-specialist nurse practitioners and physician assistants.

Program Overview
Axial spondyloarthritis (axSpA) is now thought to be a disease continuum from early, nonradiographic disease (nr-axSpA), to more advanced disease that is easily detectable by radiograph (r-axSpA, better known as ankylosing spondyloarthritis [AS]). However, these delineations are not clear cut and not without controversy.

In 2022, the nuances of the axSpA disease spectrum began to take firmer definition as experts in this rheumatologic disorder offered greater clarity toward arriving at consensus on how to detect nr-axSpA and differentiate between it and r-axSpA/AS. Additionally, 3 biologics and 1 Janus kinase (JAK) inhibitor were approved by the FDA in 2022 specifically for the treatment of nr-axSpA.

Join axSpA expert Dr. Atul Deodhar to find out what rheumatologists and other healthcare professionals who care for patients with axSpA need to know about how to evaluate nr-axSpA and what to know about the new and emerging treatments that are designed specifically for nr-axSpA.

Learning Objectives
Upon completion of this activity, participants should be able to:

Review published data that define nr-axSpA within the axSpA disease continuum to facilitate more timely diagnoses
Incorporate recently approved or emerging biologic and small-molecule treatments for appropriately selected patients with nr-axSpA, based on efficacy and safety data from clinical trials